Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden
Open Access
Abstract
Purpose The Swedish InfCareHIV cohort was established in 2003 to ensure equal and effective care of people living with HIV (PLHIV) and enable long-term follow-up. InfCareHIV functions equally as a decision support system as a quality registry, ensuring up-to-date data reported in real time. Participants InfCareHIV includes data on >99% of all people with diagnosed HIV in Sweden and up to now 13 029 have been included in the cohort. InfCareHIV includes data on HIV-related biomarkers and antiretroviral therapies (ART) and also on demographics, patient-reported outcome measures and patient-reported experience measures. Findings to date Sweden was in 2015 the first country to reach the UNAIDS (United Nations Programme on HIV/AIDS)/WHO’s 90-90-90 goals. Late diagnosis of HIV infection was identified as a key problem in the Swedish HIV-epidemic, and low-level HIV viraemia while on ART associated with all-cause mortality. Increased HIV RNA load in the cerebrospinal fluid (CSF) despite suppression of the plasma viral load was found in 5% of PLHIV, a phenomenon referred to as ‘CSF viral escape’. Dolutegravir-based treatment in PLHIV with pre-existing nucleoside reverse transcriptase inhibitor-mutations was non-inferior to protease inhibitor-based regimens. An increase of transmitted drug resistance was observed in the InfCareHIV cohort. Lower efficacy for protease inhibitors was not due to lower adherence to treatment. Incidence of type 2 diabetes and insulin resistance was high in the ageing HIV population. Despite ART, the risk of infection-related cancer as well as lung cancer was increased in PLHIV compared with HIV-negative. PLHIV were less likely successfully treated for cervical precancer and more likely to have human papillomavirus types not included in current HPV vaccines. Self-reported sexual satisfaction in PLHIV is improving and is higher in women than men. Future plans InfCareHIV provides a unique base to study and further improve long-term treatment outcomes, comorbidity management and health-related quality of life in people with HIV in Sweden.Keywords
This publication has 64 references indexed in Scilit:
- Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in SwedenInternational Journal of Cancer, 2016
- Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in SwedenThe Lancet HIV, 2016
- Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe ImmunodeficiencyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyEBioMedicine, 2016
- Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; The Barriers to HIV testing scale-Karolinska versionHealth and Quality of Life Outcomes, 2015
- Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in SwedenHIV Medicine, 2015
- Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general populationThe Lancet HIV, 2014
- Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 PatientsPLOS ONE, 2014
- Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapyJournal of Neuroinflammation, 2013
- HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral TreatmentThe Journal of Infectious Diseases, 2010